Journal of Immunology and Clinical Research

Dendritic Cell Dysfunction: A Key to HIV Spread and Persistence

Review Article | Open Access

  • 1. Division of Infectious Diseases, University of Colorado Denver, USA
  • 2. Department of Periodontics, College of Dental Medicine, Georgia Regents University, USA
+ Show More - Show Less
Corresponding Authors
Christopher Cutler, College of Dental Medicine, Georgia Regents University, 1120 15th Street GC1335, Augusta, GA, USA

Dendritic cells (DC) are central purveyors of both innate and adaptive immune responses. They initiate and modulate immune responses to pathogenic signals and play a key role in peripheral tolerance. Specifically, during HIV infection, the maturation state and abundance of DCs during infection is correlated with HIV viral load, disease progression, and immune dysregulation. While CD4 T cells are by far the most abundant HIV-infected cell, DCs express a variety of HIV co-receptors and lectin receptors that modulate HIV uptake, antigen processing, and trans-infection to T cells, thus contributing to a wide variety of immunological outcomes. In addition, the ability of HIV to exploit DC surface receptors or intracellular routing mechanisms to avoid antigen-processing machinery also contributes to viral persistence and promotes transor cis-infection of CD4 T cells. Of particular importance is the DC-specific C-type lectin DC-SIGN, which is a strong HIV binding partner and enhances both viral replication and trans-infection. Most DCs in tissues and blood are present in an immature state, but upon antigen acquisition and activation they mature. Maturing DCs acquire a phenotype that allows them to migrate through the lymphatic system and stimulate adaptive lymphocyte responses. A failure of DCs to mature, as witnessed during HIV uptake, however, leads to attenuation of antigen-specific immune responses and may significantly contribute to induction of T cell regulatory responses. These regulatory responses typically can be a consequence of low co-stimulatory molecule expression (e.g. CD40, CD80/86) or increased co-inhibitory molecule expression (e.g. PD-L1, PDL2) on DCs and production of soluble immune regulatory mediators (e.g. IDO, IL-10, TGFβ) by DCs or instructed T cells. The failure of DCs to properly process and present HIV antigens and stimulate specific adaptive responses can prevent viral clearance and aid in establishment of viral reservoirs, two of the main obstacles to a therapeutic cure.


•    Immune regulation
•    Dendritic cells
•    HIV immunity


DC: Dendritic Cell; CTL: Cytotoxic Lymphocyte; DC-SIGN: Dendritic Cell-Specific ICAM-3 Grabbing Non-integrin; HIV: HIV type 1


Miles B, Cutler CW (2014) Dendritic Cell Dysfunction: A Key to HIV Spread and Persistence. J Immunol Clin Res 2(2): 1020.


Dendritic cells (DC) are both widely dispersed in the body and are potent activators of effector immune response, which stresses their important role in HIV infection [1,2]. DCs are present at sites of HIV entry, the oral and vaginal mucosa [3,4] or circulating blood [5], and at sites of preferential HIV infection and maintenance in the lymph nodes. It has been shown that HIV-infected DCs mediate viral infection of CD4 T cell co-cultures [6,7] and it is believed that DCs transmit HIV to CD4 T cells in the lymphoid tissues in vivo [2,8], through utilization of DC-derived exosomes or an ‘immunological synapse’ [9]. Thus, DCs are important in initial encounter and response to the virus in the mucosa and blood. They are also key players in spread of infection via trans-CD4 T cell infection (or in cis), and stimulation of adaptive immune responses in attempt to eliminate virus. HIV uptake by DCs is unique in that it does not preferentially drive DC maturation and stimulate T cell instruction, but rather favors viral spread [10]. This results in dampened immunogenicity [11], and potentially drives regulatory immune responses [12].

This review focuses on how HIV is recognized and processed by DCs, the responses (and lack thereof) generated by DCs after capture, the role of DCs in HIV transfer to CD4 T cells, and the role of DCs in immunomodulatory responses to HIV.

DC antigen uptake and intracellular routing

A majority of DCs in circulation and the mucosal periphery,the main sites of early HIV interaction, are present in an immature phenotype [13]. In this state, DCs are highly adept at endocytosis and express lower levels of MHC class I and II molecules, as well as co-stimulatory molecules [14]. Immature DCs possess a wide variety of receptors, such as Fc receptors, lectins, and langerin, which allow them to efficiently bind and internalize antigen. This wide range of receptors allows for efficient receptor mediated phagocytosis of many foreign antigens. Many antigens that are internalized by DCs are routed to MHC-II expressing lysosomal vesicles where they are degraded and processed to form MHC IIpeptide complexes for T cell stimulation.

The DC-specific lectin receptor, DC-specific ICAM-grabbing non-integrin (DC-SIGN), rapidly internalizes ligands and forms DC-SIGN rich vesicles which are targeted to late endosomes and lysosomes [15]. DC-SIGN is highly expressed on DCs and binds the heavily glycosylated HIV surface glycoprotein gp120, which facilitates HIV capture DCs and enhances transmission to T cells [16]. While HIV can be transmitted independently of DC-SIGN, this molecule is of particular interest as it promotes DC migration to T cell-rich areas of lymph tissue and has also been revealed as a mechanism to subvert immune responses [17-19].

In the initial step of uptake of HIV by DCs, endocytic vesicles may play an important role in HIV trans-infection, but it is still unclear if this is a separate pathway of transmission or plays a role in synapse-mediated HIV transfer. HIV that is endocytosed by DCs may be degraded through lysosomal fusion, avoiding degradation and shuttling to an ‘infectious synapse’, or may be released as an infectious exosome. HIV has been shown to be associated with exosomes and bud from primary macrophages [20,21], but it is unclear if this process can also facilitate DCmediated trans-infection [22,23].

DC-mediated HIV transmission

In contrast to CD4 T cell infection [8], viral replication in DCs is relatively low and the frequency of HIV-infected DCs are low [24,25]. Blood DCs [26,27] and Langerhans cells [28,29] from healthy individuals are infected at low frequency with HIV in vitro [30] and in vivo [31]. This has been attributed to significantly less HIV receptor expression [32,33], intracellular routing and HIV killing [2,34], and replication-restricting host factors [35-40]. However, one study using a rhesus macaque SIV cervical infection model found that mucosal DCs accounted for 90% of SIV dissemination [41]. This highlights the importance of even a low productive infection of DCs. Through HIV uptake and dissemination the virus is able to utilize multiple pathways to transfer from DC to CD4 T cells.

The ability of DCs to trans-infect T cells has been known for some time now [42,43]. This process involves the capture of HIV on the surface of DCs [32], mobilization of DCs [44], and the clustering and polarization of both HIV particles and T cell interacting receptors on the DC surface [45]. This allows DCs to interact with CD4 T cells via this ‘immunological synapse’ and transfer HIV without necessarily becoming productively infected themselves [46]. HIV trans-infection is mediated by numerous receptors, such as C-type lectins DC-SIGN [47-49] and Langerin [50,51], but independent trans-infection models exist and this could be based on the plasticity of DC subsets mediating the HIV transfer or on HIV itself [52]. DC-SIGN, in particular, binds HIV gp120 with high affinity [53] and enhances HIV infection of CD4 T cells [54,55], but elimination of DC-SIGN has shown that transinfection is not entirely dependent on this interaction [56].

Notably, DCs have many receptors that are believed to facilitate trans-infection to CD4 T cells. These multiple pathways quite possibly stem from the distinct expression patterns of receptors with overlapping functions in DC subtypes [57]. The emerging lectin DC immunoreceptor (DCIR) [58], mannose receptor [57], BDCA-2, and peroxisome proliferator-activator receptor (PPAR)γ [59,60] are all expressed at a varying degree based on DC subtype and differentially regulate HIV binding and transfer [32,50,61,62]. These HIV-binding and transfer pathways have been shown to occur in vitro, but more in vivo studies are needed to conclude the importance and magnitude of each response.

The actual transfer of HIV to CD4 T cells is cell contactdependent and occurs through the ‘infectious synapse’. This involves a normal junction of T cell activation molecules required for APC stimulation of T cells, at which point HIV can be transferred [63,64]. Again, the cell surface makeup and subtype of DC contributes to this transfer, but these interactions have not been fully identified. HIV and its associated receptors, however, are found to be highly concentrated at the synapse. Establishment of mechanisms and dominance of contact-dependent HIV transfer in vivo are needed as this interaction facilitates viral spread and preferential CD4 T cell infection [6,65].

Interestingly, long-term DC-mediated transmission of HIV to CD4 T cells is shown to occur through virus production by DCs [34,66,67]. Immature DCs can maintain HIV for up to one week [49, 68, 69], but a majority of HIV can be degraded within one day [70,71]. This suggests that HIV may be replicated de novo in DCs and late virus transmission is from progeny virus [72]. Initial investigations have shown that establishment of productive infection of DCs leads to spread of mainly progeny virus into CD4 T cells [73]. Also, HIV gp120 binding to DC-SIGN triggers Raf1- initiated phosphorylation of p65 and facilitates HIV transcription [74,75]. While not as abundant as CD4 T cell infections, this suggests that DCs may serve as a viral reservoir to some degree in vivo. Trans- and cis-infections are not likely to be independent and exclusive, but rather overlap and contribute to HIV infection and spread in vivo.

Follicular DCs (FDC) are a non-typical DC which are found mainly in germinal centers and B cell follicles of lymphoid tissues [76]. While FDCs are not able to process and present antigen using MHC-restricted pathways, they are capable of capturing robust numbers of pathogens. FDCs are shown to trap and maintain large amounts of HIV in the follicles during infection, and thus believed to be one of the main reservoirs of infectious virus [77,78]. Importantly, FDCs have close proximity to CD4 T cells in these tissues and this juxtaposition correlates to a high concentration of productively infected follicular helper T cells [79]. In a similar fashion, it is believed that typical DCs can maintain persistent infection for long periods [80] and contribute to both cellular reservoirs and follicular helper T cell preferential infection

HIV-driven DC dysfunction

In both the blood and tissues DCs are present in an immature state that allows them to survey their local environment for antigen and respond to danger signals from nearby cells [81]. After antigen capture and activation, DCs downregulate immature surface receptors and lose their antigen capture capacity. This coincides with DCs gaining the ability to migrate to secondary lymphoid tissues [82] and present antigen to lymphocytes to drive antigen-specific adaptive immunity [13]. The presentation of peptides on MHC molecules is the first signal in stimulating effector responses. The first signal alone is not enough to drive robust effector responses. Rather, a second signal from DCs is also presented via accessory molecules to initiate specific cellular immune responses [83]. These accessory molecules (e.g. CD40, CD83, CD80/86) become expressed during the maturation process of DCs after they acquire antigen [84]. This second signal is crucial for a robust antigen-specific cellular response and any deficiencies here result in attenuated effector T cell and B cell responses.

Interestingly, HIV infection of DCs does not result in typical DC functional maturation [85,86]. HIV infected cells have a definitive lack of accessory molecule expression [87-89], but may be stimulated to produce a typical maturation response [90]. This lack of DC response also results in biased cytokine production [91], poor virus peptide processing [92], and DC apoptosis and necrosis [93,94]. Toll-like receptors (TLR) 7 and 8, crucial in recognizing viral RNA and guiding abortive HIV replication [95,96], are less responsive in HIV-infected subjects which could provide a lack maturation marker expression and cytokine production [97]. Evidence shows that TLR8 can be exploited in a DC-SIGN-dependent manner to yield productive infection of DCs [74]. Also, in acute infections, DCs from HIVinfected individuals are found to have inhibited interferon (IFN) production [98]. In contrast, other studies have found normal DC responses to TLR 7/8 agonists and normal IFN production ex vivo [99]. This suggests that both DC subtype and the stage of HIV infection (among various other factors) may play important roles in tracking DC function and linking HIV progression with DC-mediated immune outcomes.

The inflammatory microenvironment also plays a large role in DC maturation and function. Plasma from HIVinfected individuals, at both acute and chronic stages, inhibits inflammatory cytokine production, TLR activation, and T cell polarization [100-102]. This is likely to be an indirect result of viral increases during disease progression. Hence, with increasing levels of virus present, DCs become more affected and more dysregulated. Immature DCs subsequently fail to drive effector T cell proliferation and activation during HIV infection [103,104]. One study showed that peripheral blood DCs from HIV-infected individuals were inefficient at stimulating HIV antigen-specific T cells [99,105]. Further, a direct injection of immature DCs in the context of HIV infection was shown to specifically inhibit effector T cell function [106], whereas mature DCs were able to stimulate HIV immunity [107]. Faulty immune stimulatory responses from immature DCs, combined with the inability to clear HIV and transinfect T cells, heavily tips the scales in favor of HIV progression.

Chronic inflammation, mediated in part through the activity of DCs, is also associated with co-infections and this is believed to advance progressive HIV infection [108-110]. This is due in part to constant immune activation, which is one of the indicators of HIV progression. Mucosal [111,112] and blood DCs [113,114] have been shown to be dysregulated by microbial pathogens, which may assist in chronic immune activation and HIV spread through DC-mediated dissemination [115]. Specifically, gut mucosal DCs have high rates of inflammatory mediators [116] and blood DCs infected with an oral pathogen upregulate co-receptor expression and migratory capacity [117,118]. Prolonged type-I IFN production due to chronic inflammation has been correlated with disease progression and may contribute to immune exhaustion [119]. Bacterial uptake and activation of pyroptosis can also trigger IL-1β production and further extend inflammatory conditions [120]. Co-infection can result in a further alteration of DC activity or contribute to the chronic inflammatory response. Patients with both HIV infection and opportunistic infections have upregulated TLR 2 and 4 on the surface of DCs, further contributing to immune imbalances [121]. Microbial pathogens, their translocation, and imbalance in blood DC numbers are believed to support chronic HIV infection [108,115,122-124].

The frequencies of DCs are immediately lowered during acute HIV infection and maintained throughout chronic infection [125-127]. These reductions correlate with increased viral load and a continual dampening of effector cell activity. Type I IFN is produced during HIV infection, which can negatively influence DC numbers through inhibition of DC differentiation in vivo [128]. In an acute SIV infection model, rhesus macaques were observed to have an influx of DCs from blood into lymphoid tissues at viral set point. This correlated with high rates of DC apoptosis [129], thus resulting in reduction of DCs in blood and tissues [130,131]. Blood DCs have also been found to have pro-apoptotic phenotypes that correlate with reduced blood DCs and increased viral load [132]

It should be noted that many of the immunomodulatory effects of HIV-infected DCs is thought to be produced through faulty T helper cell priming, weak T cell proliferation, and cytokine production. In contrast, HIV-infected DCs are thought to have the ability to efficiently activate cytotoxic lymphocytes (CTL) [133,134], albeit lower levels of CTL have been described [135]. The HIV regulatory protein Nef has been shown to downregulate MHC class I molecules on DCs, thus potentially contributing to inhibition of CTL response [136,137]. This highlights an area in need of further studies, as inefficient accessory molecule expression may be subverted for CTL activation.

Role of immature dendritic cells in immune regulation

Another emerging consequence of faulty DC maturation is the production of regulatory mediators and development of regulatory T cells (Treg) [138,139]. Most importantly, immature DCs have been found to be sources of the cellular proliferation regulating enzyme, indoleamine 2, 3- deoxygenase (IDO) [140,141] and the important regulatory T cell cytokines IL10 [87,142] and TGFβ. HIV-infected DCs have been shown to produce IDO [143-145], at least partially dependent on DC-SIGN interaction [146], resulting in stimulation of T cells to produce IL-10 and TGFβ in co-culture [87,147]. This promotes regulatory responses, which are thought to facilitate dampening of immune responses in progression from acute to chronic infection. Hence, a productive DC infection can undermine effector T cell responses to eliminate HIV.

Effector cell exhaustion and regulatory immune responses frequently occur during chronic inflammatory conditions. Type-I IFN leads to increasing expression of programmeddeath ligand 1 (PD-L1) on DCs [148], which is a key mediator of effector cell senescence [149]. This is a reversible mechanism as blockade of PD-L1 on DCs can promote T cell proliferation and activation [150,151]. Additionally, these DCs can upregulate IL10 production and downregulate IFNy production in T cells. The production of IDO during inflammatory conditions can facilitate the conversion of Th17 cells to Treg cells [152,153]. In addition, inflammatory cytokines can upregulate TNF-related apoptosisinducing ligand (TRAIL) or death receptors on DCs that contribute to CD4 T cell depletion [154,155].

Tregs are increased in the blood of HIV-infected individuals [156-158]. Also, Tregs increase in the lymph nodes during HIV progressions [159-161]. Tregs are potent inhibitors of HIVspecific CD4 and CD8 T cell responses [162] and this is likely a mechanism that contributes to decreased CTL response and to maintenance of HIV-infected reservoirs in the lymphoid tissues [163]. These increased Treg populations arise from both direct and indirect production of IL-10 and TGFβ during HIV infection and the production of IDO during HIV or other infections. IDO regulates proliferation and activation of T cells, but also coordinates differentiation of Tregs. These regulatory molecules either drive naïve T cell populations to differentiate into Tregs or drive conversion of existing effector cells to take on a regulatory phenotype. Production of immunoregulatory mediators directly from DCs or production from T cells stimulated by dysregulated DCs leads to production of a regulatory immune phenotype that favors HIV persistence and replication.

In addition to increased Tregs in the blood and lymphoid tissues of HIV-infected individuals, the Tregs showed heightened levels of activation [164]. These Tregs express increased levels of the contact inhibitor molecules CTLA-4 [165,166] and GITR [161], as well as secrete higher levels of the regulatory cytokine TGFβ [167]. This increase in activity not only makes Tregs more efficient in inhibiting effector molecule function, but also further promotes Treg differentiation. This positive feedback further disrupts effector cell response and promotes HIV persistence. Another mechanism of immune regulation is through adenosine deaminase activity [168]. These surface receptors play a role in HIV outcomes [169,170]. Further studies elucidating the exact viral and host components generating regulatory responses are needed to provide counteracting measures.



As a result of intricate studies that have been performed in the last few years it is now clear that DCs play an essential role in HIV progression. They are involved in every stage of HIV infection, from initial recognition and transmission, to effector immune response, and to chronic immune activation. Due to the dysregulation and manipulation of DCs by HIV and other co-infections, DCs are believed to contribute to establishment of viral reservoirs and immunoregulatory responses that favor chronic infection. Further investigations to determine specific mechanisms of HIV and DC interactions will provide the framework to reverse this manipulation and harness the ability of DCs to mount a robust, protective immune response. This will be beneficial in finding new targets for HIV therapeutic approaches and, as DCs are ideal for cell-based vaccines, move research closer to the overall goal of an effective HIV vaccine.


Funding was provided by the NIH/NIAID T32 5T32AI007447-22 to BM and NIH/NIDCR R01 DE14328 to CWC.


1. Borrow P, Evans CF, Oldstone MB. Virus-induced immunosuppression: immune system-mediated destruction of virus-infected dendritic cells results in generalized immune suppression. J Virol. 1995; 69: 1059- 1070.

2. Piguet V, Steinman RM. The interaction of HIV with dendritic cells: outcomes and pathways. Trends Immunol. 2007; 28: 503-510.

3. Belyakov IM, Hammond SA, Ahlers JD, Glenn GM, Berzofsky JA. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J Clin Invest. 2004; 113: 998-1007.

4. Ochiel DO, Ochsenbauer C, Kappes JC, Ghosh M, Fahey JV, Wira CR. Uterine epithelial cell regulation of DC-SIGN expression inhibits transmitted/founder HIV-1 trans infection by immature dendritic cells. PLoS One. 2010; 5: e14306.

5. Patterson S, Knight SC. Susceptibility of human peripheral blood dendritic cells to infection by human immunodeficiency virus. J Gen Virol. 1987; 68 : 1177-1181.

6. Cameron PU, Freudenthal PS, Barker JM, Gezelter S, Inaba K, Steinman RM. Dendritic cells exposed to human immunodeficiency virus type1 transmit a vigorous cytopathic infection to CD4+ T cells. Science. 1992; 257: 383-387.

7. Pope M, Betjes MG, Romani N, Hirmand H, Cameron PU, Hoffman L, et al. Conjugates of dendritic cells and memory T lymphocytes from skin facilitate productive infection with HIV-1. Cell. 1994; 78: 389-398.

8. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature. 2002; 417: 95-98.

9. Wu L, KewalRamani VN. Dendritic-cell interactions with HIV: infection and viral dissemination. Nat Rev Immunol. 2006; 6: 859-868.

10. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med. 2000; 6: 207-210.

11. Pitcher CJ, Quittner C, Peterson DM, Connors M, Koup RA, Maino VC, et al. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med. 1999; 5: 518-525.

12. Aandahl EM, Michaëlsson J, Moretto WJ, Hecht FM, Nixon DF. Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol. 2004; 78: 2454-2459.

13. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol. 1997; 9: 10-16.

14. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell. 2001; 106: 255-258.

15. Engering A, Geijtenbeek TB, van Vliet SJ, Wijers M, van Liempt E, Demaurex N, et al. The dendritic cell-specific adhesion receptor DCSIGN internalizes antigen for presentation to T cells. J Immunol. 2002; 168: 2118-2126.

16. Geijtenbeek TB, van Duijnhoven GC, van Vliet SJ, Krieger E, Vriend G, Figdor CG, et al. Identification of different binding sites in the dendritic cell-specific receptor DC-SIGN for intercellular adhesion molecule 3 and HIV-1. J Biol Chem. 2002; 277: 11314-11320.

17. van Kooyk Y, Geijtenbeek TB. DC-SIGN: escape mechanism for pathogens. Nat Rev Immunol. 2003; 3: 697-709.

18. Cunningham AL, Harman AN, Donaghy H. DC-SIGN ‘AIDS’ HIV immune evasion and infection. Nat Immunol. 2007; 8: 556-558.

19. den Dunnen J, Gringhuis SI, Geijtenbeek TB. Innate signaling by the C-type lectin DC-SIGN dictates immune responses. Cancer Immunol Immunother. 2009; 58: 1149-1157.

20. Nguyen DG, Booth A, Gould SJ, Hildreth JE. Evidence that HIV budding in primary macrophages occurs through the exosome release pathway. J Biol Chem. 2003; 278: 52347-52354.

21. Welsch S, Keppler OT, Habermann A, Allespach I, Krijnse-Locker J, Kräusslich HG. HIV-1 buds predominantly at the plasma membrane of primary human macrophages. PLoS Pathog. 2007; 3: e36.

22. Wiley RD, Gummuluru S. Immature dendritic cell-derived exosomes can mediate HIV-1 trans infection. Proc Natl Acad Sci U S A. 2006; 103: 738-743.

23. Izquierdo-Useros N, Naranjo-Gómez M, Erkizia I, Puertas MC, Borràs FE, Blanco J, et al. HIV and mature dendritic cells: Trojan exosomes riding the Trojan horse? PLoS Pathog. 2010; 6: e1000740.

24. Steinman RM, Granelli-Piperno A, Pope M, Trumpfheller C, Ignatius R, Arrode G, et al. The interaction of immunodeficiency viruses with dendritic cells. Curr Top Microbiol Immunol. 2003; 276: 1-30.

25. Granelli-Piperno A, Delgado E, Finkel V, Paxton W, Steinman RM. Immature dendritic cells selectively replicate macrophagetropic (M-tropic) human immunodeficiency virus type 1, while mature cells efficiently transmit both M-and T-tropic virus to T cells. J virol. 1998; 72: 2733-2737.

26. Donaghy H, Pozniak A, Gazzard B, Qazi N, Gilmour J, Gotch F, et al. Loss of blood CD11c(+) myeloid and CD11c(-) plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load. Blood. 2001; 98: 2574-2576.

27. Smed-Sörensen A, Loré K, Vasudevan J, Louder MK, Andersson J, Mascola JR, et al. Differential susceptibility to human immunodeficiency virus type 1 infection of myeloid and plasmacytoid dendritic cells. J Virol. 2005; 79: 8861-8869.

28. Kawamura T, Gulden FO, Sugaya M, McNamara DT, Borris DL, Lederman MM, et al. R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms. Proc Natl Acad Sci U S A. 2003; 100: 8401-8406.

29. Zaitseva M, Blauvelt A, Lee S, Lapham CK, Klaus-Kovtun V, Mostowski H, et al. Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: implications for HIV primary infection. Nat Med. 1997; 3: 1369-1375.

30. Cameron PU, Lowe MG, Crowe SM, O’Doherty U, Pope M, Gezelter S, et al. Susceptibility of dendritic cells to HIV-1 infection in vitro. J Leukoc Biol. 1994; 56: 257-265.

31. McIlroy D, Autran B, Cheynier R, Wain-Hobson S, Clauvel JP, Oksenhendler E, et al. Infection frequency of dendritic cells and CD4+ T lymphocytes in spleens of human immunodeficiency virus-positive patients. J Virol. 1995; 69: 4737-4745.

32. Granelli-Piperno A, Moser B, Pope M, Chen D, Wei Y, Isdell F, et al. Efficient interaction of HIV-1 with purified dendritic cells via multiple chemokine coreceptors. J Exp Med. 1996; 184: 2433-2438.

33. Rubbert A, Combadiere C, Ostrowski M, Arthos J, Dybul M, Machado E, et al. Dendritic cells express multiple chemokine receptors used as coreceptors for HIV entry. J Immunol. 1998; 160: 3933-3941.

34. Nobile C, Petit C, Moris A, Skrabal K, Abastado JP, Mammano F, et al. Covert human immunodeficiency virus replication in dendritic cells and in DC-SIGN-expressing cells promotes long-term transmission to lymphocytes. J Virol. 2005; 79: 5386-5399.

35. Pion M, Granelli-Piperno A, Mangeat B, Stalder R, Correa R, Steinman RM, et al. APOBEC3G/3F mediates intrinsic resistance of monocytederived dendritic cells to HIV-1 infection. J Exp Med. 2006; 203: 2887- 2893.

36. Pertel T, Hausmann S, Morger D, Züger S, Guerra J, Lascano J, et al. TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature. 2011; 472: 361-365.

37. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Ségéral E, et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature. 2011; 474: 654- 657.

38. Lahouassa H, Daddacha W, Hofmann H, Ayinde D, Logue EC, Dragin L, et al. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat immunol. 2012; 13: 223-228.

39. Goldstone DC, Ennis-Adeniran V, Hedden JJ, Groom HC, Rice GI, Christodoulou E, et al. HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature. 2011; 480: 379-382.

40. Stopak KS, Chiu YL, Kropp J, Grant RM, Greene WC. Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. J Biol Chem. 2007; 282: 3539-3546.

41. Hu Q, Frank I, Williams V, Santos JJ, Watts P, Griffin GE, et al. Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. J Exp Med. 2004; 199: 1065-1075.

42. .Loré K, Smed-Sörensen A, Vasudevan J, Mascola JR, Koup RA. Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4+ T cells. J Exp Med. 2005; 201: 2023-2033.

43. Weissman D, Ni H, Scales D, Dude A, Capodici J, McGibney K, et al. HIV gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response. J Immunol. 2000; 165: 4710-4717.

44. Aggarwal A, Iemma TL, Shih I, Newsome TP, McAllery S, Cunningham AL, et al. Mobilization of HIV spread by diaphanous 2 dependent filopodia in infected dendritic cells. PLoS Pathog. 2012; 8: e1002762.

45. McDonald D, Wu L, Bohks SM, KewalRamani VN, Unutmaz D, Hope TJ. Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science. 2003; 300: 1295-1297.

46. Turville SG, Santos JJ, Frank I, Cameron PU, Wilkinson J, MirandaSaksena M, et al. Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cells. Blood. 2004; 103: 2170- 2179.

47. Arrighi JF, Pion M, Garcia E, Escola JM, van Kooyk Y, Geijtenbeek TB, et al. DC-SIGN-mediated infectious synapse formation enhances X4 HIV 1 transmission from dendritic cells to T cells. J Exp Med. 2004; 200: 1279-1288. 

48. Engering A, Van Vliet SJ, Geijtenbeek TB, Van Kooyk Y. Subset of DC-SIGN(+) dendritic cells in human blood transmits HIV-1 to T lymphocytes. Blood. 2002; 100: 1780-1786.

49. Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel J, et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell. 2000; 100: 587- 597.

50. Figdor CG, van Kooyk Y, Adema GJ. C-type lectin receptors on dendritic cells and Langerhans cells. Nat Rev Immunol. 2002; 2: 77-84.

51. Hladik F, McElrath MJ. Setting the stage: host invasion by HIV. Nat Rev Immunol. 2008; 8: 447-457.

52. Mercier SK, Donaghy H, Botting RA, Turville SG, Harman AN, Nasr N, et al. The microvesicle component of HIV-1 inocula modulates dendritic cell infection and maturation and enhances adhesion to and activation of T lymphocytes. PLoS Pathog. 2013; 9: e1003700.

53. Turville SG, Arthos J, Donald KM, Lynch G, Naif H, Clark G, et al. HIV gp120 receptors on human dendritic cells. Blood. 2001; 98: 2482- 2488.

54. Sol-Foulon N, Moris A, Nobile C, Boccaccio C, Engering A, Abastado JP, et al. HIV-1 Nef-induced upregulation of DC-SIGN in dendritic cells promotes lymphocyte clustering and viral spread. Immunity. 2002; 16: 145-155.

55. Kwon DS, Gregorio G, Bitton N, Hendrickson WA, Littman DR. DC-SIGNmediated internalization of HIV is required for trans-enhancement of T cell infection. Immunity. 2002; 16: 135-144.

56. Boggiano C, Manel N, Littman DR. Dendritic cell-mediated transenhancement of human immunodeficiency virus type 1 infectivity is independent of DC-SIGN. J Virol. 2007; 81: 2519-2523.

57. Turville SG, Cameron PU, Handley A, Lin G, Pöhlmann S, Doms RW, et al. Diversity of receptors binding HIV on dendritic cell subsets. Nat Immunol. 2002; 3: 975-983.

58. Lambert AA, Gilbert C, Richard M, Beaulieu AD, Tremblay MJ. The C-type lectin surface receptor DCIR acts as a new attachment factor for HIV-1 in dendritic cells and contributes to trans- and cis-infection pathways. Blood. 2008; 112: 1299-1307.

59. Hanley TM, Blay Puryear W, Gummuluru S, Viglianti GA. PPARgamma and LXR signaling inhibit dendritic cell-mediated HIV-1 capture and trans-infection. PLoS Pathog. 2010; 6: e1000981.

60. Appel S, Mirakaj V, Bringmann A, Weck MM, Grünebach F, Brossart P. PPAR-gamma agonists inhibit toll-like receptor-mediated activation of dendritic cells via the MAP kinase and NF-kappaB pathways. Blood. 2005; 106: 3888-3894.

61. Beignon AS, McKenna K, Skoberne M, Manches O, DaSilva I, Kavanagh DG, et al. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest. 2005; 115: 3265-3275.

62. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 1996; 85: 1135-1148.

63. Felts RL, Narayan K, Estes JD, Shi D, Trubey CM, Fu J, et al. 3D visualization of HIV transfer at the virological synapse between dendritic cells and T cells. Proc Natl Acad Sci USA. 2010; 107: 13336- 13341.

64. Nikolic DS, Lehmann M, Felts R, Garcia E, Blanchet FP, Subramaniam S, et al. HIV-1 activates Cdc42 and induces membrane extensions in immature dendritic cells to facilitate cell-to-cell virus propagation. Blood. 2011; 118: 4841-4852.

65. Sewell AK, Price DA. Dendritic cells and transmission of HIV-1. Trends Immunol. 2001; 22: 173-175.

66. Pope M, Gezelter S, Gallo N, Hoffman L, Steinman RM. Low levels of HIV-1 infection in cutaneous dendritic cells promote extensive viral replication upon binding to memory CD4+ T cells. J Exp Med. 1995; 182: 2045-2056.

67. Garcia E, Nikolic DS, Piguet V. HIV-1 replication in dendritic cells occurs through a tetraspanin-containing compartment enriched in AP-3. Traffic. 2008; 9: 200-214.

68. Trumpfheller C, Park CG, Finke J, Steinman RM, Granelli-Piperno A. Cell type-dependent retention and transmission of HIV-1 by DC-SIGN. Int Immunol. 2003; 15: 289-298.

69. Coleman CM, Wu L. HIV interactions with monocytes and dendritic cells: viral latency and reservoirs. Retrovirology. 2009; 6: 51.

70. Moris A, Pajot A, Blanchet F, Guivel-Benhassine F, Salcedo M, Schwartz O. Dendritic cells and HIV-specific CD4+ T cells: HIV antigen presentation, T-cell activation, and viral transfer. Blood. 2006; 108: 1643-1651.

71. Moris A, Nobile C, Buseyne F, Porrot F, Abastado JP, Schwartz O. DC-SIGN promotes exogenous MHC-I-restricted HIV-1 antigen presentation. Blood. 2004; 103: 2648-2654.

72. Granelli-Piperno A, Finkel V, Delgado E, Steinman RM. Virus replication begins in dendritic cells during the transmission of HIV-1 from mature dendritic cells to T cells. Curr Biol. 1999; 9: 21-29.

73. Holl V, Xu K, Peressin M, Lederle A, Biedma ME, Delaporte M, et al. Stimulation of HIV-1 replication in immature dendritic cells in contact with primary CD4 T or B lymphocytes. J Virol. 2010; 84: 4172-4182.

74. Gringhuis SI, van der Vlist M, van den Berg LM, den Dunnen J, Litjens M, Geijtenbeek TB. HIV-1 exploits innate signaling by TLR8 and DCSIGN for productive infection of dendritic cells. Nat Immunol. 2010; 11: 419-426.

75. Hodges A, Sharrocks K, Edelmann M, Baban D, Moris A, Schwartz O, et al. Activation of the lectin DC-SIGN induces an immature dendritic cell phenotype triggering Rho-GTPase activity required for HIV-1 replication. Nat Immunol. 2007; 8: 569-577.

76. Tew JG, Kosco MH, Burton GF, Szakal AK. Follicular dendritic cells as accessory cells. Immunol Rev. 1990; 117: 185-211.

77. Burton GF, Keele BF, Estes JD, Thacker TC, Gartner S. Follicular dendritic cell contributions to HIV pathogenesis. Semin immunol; 2002: 14; 275-284.

78. Smith BA, Gartner S, Liu Y, Perelson AS, Stilianakis NI, Keele BF, et al. Persistence of infectious HIV on follicular dendritic cells. J Immunol. 2001; 166: 690-696.

79. Spiegel H, Herbst H, Niedobitek G, Foss HD, Stein H. Follicular dendritic cells are a major reservoir for human immunodeficiency virus type 1 in lymphoid tissues facilitating infection of CD4+ T-helper cells. Am J Pathol. 1992; 140: 15-22.

80. Popov S, Chenine AL, Gruber A, Li PL, Ruprecht RM. Long-term productive human immunodeficiency virus infection of CD1a-sorted myeloid dendritic cells. J Virol. 2005; 79: 602-608.

81. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000; 18: 767- 811.

82. Sallusto F, Schaerli P, Loetscher P, Schaniel C, Lenig D, Mackay CR, et al. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol. 1998; 28: 2760-2769. 

83. Kapsenberg ML. Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol. 2003; 3: 984-993.

84. Masten BJ, Yates JL, Pollard Koga AM, Lipscomb MF. Characterization of accessory molecules in murine lung dendritic cell function: roles for CD80, CD86, CD54, and CD40L. Am J Respir Cell Mol Biol. 1997; 16: 335-342.

85. Donaghy H, Gazzard B, Gotch F, Patterson S. Dysfunction and infection of freshly isolated blood myeloid and plasmacytoid dendritic cells in patients infected with HIV-1. Blood. 2003; 101: 4505-4511.

86. Anthony DD, Yonkers NL, Post AB, Asaad R, Heinzel FP, Lederman MM, et al. Selective impairments in dendritic cell-associated function distinguish hepatitis C virus and HIV infection. J Immunol. 2004; 172: 4907-4916.

87. Granelli-Piperno A, Golebiowska A, Trumpfheller C, Siegal FP, Steinman RM. HIV-1-infected monocyte-derived dendritic cells do not undergo maturation but can elicit IL-10 production and T cell regulation. Proc Natl Acad Sci U S A. 2004; 101: 7669-7674.

88. Loré K, Sönnerborg A, Broström C, Goh LE, Perrin L, McDade H, et al. Accumulation of DC-SIGN+CD40+ dendritic cells with reduced CD80 and CD86 expression in lymphoid tissue during acute HIV-1 infection. AIDS. 2002; 16: 683-692.

89. Granelli-Piperno A, Shimeliovich I, Pack M, Trumpfheller C, Steinman RM. HIV-1 selectively infects a subset of nonmaturing BDCA1-positive dendritic cells in human blood. J Immunol. 2006; 176: 991-998.

90. De Keersmaecker B, Heirman C, Corthals J, Empsen C, van Grunsven LA, Allard SD, et al. The combination of 4-1BBL and CD40L strongly enhances the capacity of dendritic cells to stimulate HIV-specific T cell responses. J Leukoc Biol. 2011; 89: 989-999.

91. Izmailova E, Bertley FM, Huang Q, Makori N, Miller CJ, Young RA, et al. HIV-1 Tat reprograms immature dendritic cells to express chemoattractants for activated T cells and macrophages. Nat Med. 2003; 9: 191-197.

92. Loré K, Betts MR, Brenchley JM, Kuruppu J, Khojasteh S, Perfetto S, et al. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses. J Immunol. 2003; 171: 4320-4328.

93. Herbeuval JP, Boasso A, Grivel JC, Hardy AW, Anderson SA, Dolan MJ, et al. TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells. Blood. 2005; 105: 2458-2464.

94. Gougeon ML. Apoptosis as an HIV strategy to escape immune attack. Nat Rev Immunol. 2003; 3: 392-404.

95. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004; 303: 1526-1529.

96. Wille-Reece U, Wu CY, Flynn BJ, Kedl RM, Seder RA. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. J Immunol. 2005; 174: 7676-7683.

97. Martinson JA, Roman-Gonzalez A, Tenorio AR, Montoya CJ, Gichinga CN, Rugeles MT, et al. Dendritic cells from HIV-1 infected individuals are less responsive to toll-like receptor (TLR) ligands. Cell Immunol. 2007; 250: 75-84.

98. Schlaepfer E, Audigé A, Joller H, Speck RF. TLR7/8 triggering exerts opposing effects in acute versus latent HIV infection. J Immunol. 2006; 176: 2888-2895.

99. Sabado RL, O’Brien M, Subedi A, Qin L, Hu N, Taylor E, et al. Evidence of dysregulation of dendritic cells in primary HIV infection. Blood. 2010; 116: 3839-3852.

100. Mailliard RB, Son YI, Redlinger R, Coates PT, Giermasz A, Morel PA, et al. Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol. 2003; 171: 2366-2373.

101. Frleta D, Ochoa CE, Kramer HB, Khan SA, Stacey AR, Borrow P, et al. HIV-1 infection-induced apoptotic microparticles inhibit human DCs via CD44. J Clin Invest. 2012; 122: 4685-4697.

102. Miller EA, Spadaccia MR, O’Brien MP, Rolnitzky L, Sabado R, Manches O, et al. Plasma factors during chronic HIV-1 infection impair IL12 secretion by myeloid dendritic cells via a virus-independent pathway. J Acquir Immune Defic Syndr. 2012; 61; 535-544.

103. Macatonia SE, Patterson S, Knight SC. Suppression of immune responses by dendritic cells infected with HIV. Immunology. 1989; 67: 285-289.

104. Roberts M, Gompels M, Pinching AJ, Knight SC. Dendritic cells from HIV-1 infected individuals show reduced capacity to stimulate autologous T-cell proliferation. Immunol Lett. 1994; 43: 39-43.

105. Van Gulck E, Cools N, Atkinson D, Bracke L, Vereecken K, Vekemans M, et al. Interleukin-12p70 expression by dendritic cells of HIV-1- infected patients fails to stimulate gag-specific immune responses. Clin Dev Immunol. 2012; 2012: 184979.

106. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med. 2001; 193: 233-238.

107. Dhodapkar MV, Steinman RM, Sapp M, Desai H, Fossella C, Krasovsky J, et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest. 1999; 104: 173-180.

108. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006; 12: 1365-1371.

109. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA. 2002; 288: 199- 206.

110. Kirschner D. Dynamics of co-infection with M. Tuberculosis and HIV1. Theor Popul Biol. 1999; 55: 94-109. 111. Cutler CW, Jotwani R. Dendritic cells at the oral mucosal interface. J Dent Res. 2006; 85: 678-689.

112. Strober W. The multifaceted influence of the mucosal microflora on mucosal dendritic cell responses. Immunity. 2009; 31: 377-388.

113. Miles B, Scisci E, Carrion J, Sabino GJ, Genco CA, Cutler CW. Noncanonical dendritic cell differentiation and survival driven by a bacteremic pathogen. J Leukoc Biol. 2013; 94: 281-289.

114. Connolly SF, Kusner DJ. The regulation of dendritic cell function by calcium-signaling and its inhibition by microbial pathogens. Immunol Res. 2007; 39: 115-127.

115. Palucka K, Banchereau J. How dendritic cells and microbes interact to elicit or subvert protective immune responses. Curr Opin Immunol. 2002; 14: 420-431.

116. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007; 448: 427-434.

117. Carrion J, Scisci E, Miles B, Sabino GJ, Zeituni AE, Gu Y, et al. Microbial carriage state of peripheral blood dendritic cells (DCs) in chronic periodontitis influences DC differentiation, atherogenic potential. J Immunol. 2012; 189: 3178-3187.

118. Miles B, Zakhary I, El-Awady A, Scisci E, Carrion J, O’Neill JC, et al. Secondary lymphoid organ homing phenotype of human myeloid dendritic cells disrupted by an intracellular oral pathogen. Infect Immun. 2014; 82: 101-111.

119. Mandl JN, Barry AP, Vanderford TH, Kozyr N, Chavan R, Klucking S, et al. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat Med. 2008; 14: 1077-1087.

120. Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: host cell death and inflammation. Nat Rev Microbiol. 2009; 7: 99-109.

121. Hernández JC, Arteaga J, Paul S, Kumar A, Latz E, Urcuqui-Inchima S. Up-regulation of TLR2 and TLR4 in dendritic cells in response to HIV type 1 and coinfection with opportunistic pathogens. AIDS Res Hum Retroviruses. 2011; 27: 1099-1109.

122. Levy JA. The importance of the innate immune system in controlling HIV infection and disease. Trends Immunol. 2001; 22: 312-316.

123. Geijtenbeek TB, Van Vliet SJ, Koppel EA, Sanchez-Hernandez M, Vandenbroucke-Grauls CM, Appelmelk B, et al. Mycobacteria target DC-SIGN to suppress dendritic cell function. J Exp Med. 2003; 197: 7-17.

124. Noursadeghi M, Katz DR, Miller RF. HIV-1 infection of mononuclear phagocytic cells: the case for bacterial innate immune deficiency in AIDS. Lancet Infect Dis. 2006; 6: 794-804.

125. Chehimi J, Campbell DE, Azzoni L, Bacheller D, Papasavvas E, Jerandi G, et al. Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J Immunol. 2002; 168: 4796-4801.

126. Grassi F, Hosmalin A, McIlroy D, Calvez V, Debré P, Autran B. Depletion in blood CD11c-positive dendritic cells from HIV-infected patients. AIDS. 1999; 13: 759-766.

127. Pacanowski J, Kahi S, Baillet M, Lebon P, Deveau C, Goujard C, et al. Reduced blood CD123+ (lymphoid) and CD11c+ (myeloid) dendritic cell numbers in primary HIV-1 infection. Blood. 2001; 98: 3016- 3021.

128. Feldman S, Stein D, Amrute S, Denny T, Garcia Z, Kloser P, et al. Decreased interferon-alpha production in HIV-infected patients correlates with numerical and functional deficiencies in circulating type 2 dendritic cell precursors. Clin Immunol. 2001; 101: 201-210.

129. Laforge M, Campillo-Gimenez L, Monceaux V, Cumont MC, Hurtrel B, Corbeil J, et al. HIV/SIV infection primes monocytes and dendritic cells for apoptosis. PLoS Pathog. 2011; 7: e1002087.

130. Brown KN, Wijewardana V, Liu X, Barratt-Boyes SM. Rapid influx and death of plasmacytoid dendritic cells in lymph nodes mediate depletion in acute simian immunodeficiency virus infection. PLoS pathogens. 2009; 5: e1000413.

131. Wijewardana V, Soloff AC, Liu X, Brown KN, Barratt-Boyes SM. Early myeloid dendritic cell dysregulation is predictive of disease progression in simian immunodeficiency virus infection. PLoS Pathog. 2010; 6: e1001235.

132. Dillon SM, Friedlander LJ, Rogers LM, Meditz AL, Folkvord JM, Connick E, et al. Blood myeloid dendritic cells from HIV-1- infected individuals display a proapoptotic profile characterized by decreased Bcl-2 levels and by caspase-3+ frequencies that are associated with levels of plasma viremia and T cell activation in an exploratory study. J virol. 2011; 85: 397-409.

133. Climent N, Guerra S, García F, Rovira C, Miralles L, Gómez CE, et al. Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals. PLoS One. 2011; 6: e19644.

134. Gruber A, Kan-Mitchell J, Kuhen KL, Mukai T, Wong-Staal F. Dendritic cells transduced by multiply deleted HIV-1 vectors exhibit normal phenotypes and functions and elicit an HIV-specific cytotoxic T-lymphocyte response in vitro Presented in part at the 1999 International Meeting of the Institute of Human Virology, Baltimore, MD, August 28-September 2, 1999 (J Hum Virol 2: abstract 301, 1999). Blood. 2000; 96: 1327-1333.

135. Gray CM, Lawrence J, Schapiro JM, Altman JD, Winters MA, Crompton M, et al. Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). J Immunol. 1999; 162: 1780-1788.

136. Andrieu M, Chassin D, Desoutter J-F, Bouchaert I, Baillet M, Hanau D, et al. Downregulation of Major Histocompatibility Class I on Human Dendritic Cells by HIV Nef Impairs Antigen Presentation to HIVSpecific CD8+ T Lymphocytes. AIDS Res Hum Retroviruses.. 2001; 17: 1365-1370.

137. Shinya E, Owaki A, Shimizu M, Takeuchi J, Kawashima T, Hidaka C, et al. Endogenously expressed HIV-1 nef down-regulates antigenpresenting molecules, not only class I MHC but also CD1a, in immature dendritic cells. Virology. 2004; 326: 79-89.

138. Huang H, Dawicki W, Zhang X, Town J, Gordon JR. Tolerogenic dendritic cells induce CD4+CD25hiFoxp3+ regulatory T cell differentiation from CD4+CD25-/loFoxp3- effector T cells. J Immunol. 2010; 185: 5003-5010.

139. Krathwohl MD, Schacker TW, Anderson JL. Abnormal presence of semimature dendritic cells that induce regulatory T cells in HIVinfected subjects. J Infect Dis. 2006; 193: 494-504.

140. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004; 4: 762-774.

141. Terness P, Bauer TM, Röse L, Dufter C, Watzlik A, Simon H, et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med. 2002; 196: 447- 457.

142. Levings MK, Gregori S, Tresoldi E, Cazzaniga S, Bonini C, Roncarolo MG. Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood. 2005; 105: 1162-1169.

143. Boasso A, Hardy AW, Anderson SA, Dolan MJ, Shearer GM. HIVinduced type I interferon and tryptophan catabolism drive T cell dysfunction despite phenotypic activation. PLoS One. 2008; 3: e2961.

144. Boasso A, Herbeuval JP, Hardy AW, Anderson SA, Dolan MJ, Fuchs D, et al. HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. Blood. 2007; 109: 3351-3359.

145. Manches O, Munn D, Fallahi A, Lifson J, Chaperot L, Plumas J, et al. HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism. J Clin Invest. 2008; 118: 3431-3439.

146. Nair MP, Schwartz SA, Mahajan SD, Tsiao C, Chawda RP, Whitney R, et al. Drug abuse and neuropathogenesis of HIV infection: role of DCSIGN and IDO. J Neuroimmunol. 2004; 157: 56-60.

147. Rouse BT, Sarangi PP, Suvas S. Regulatory T cells in virus infections. Immunol Rev. 2006; 212: 272-286.

148. Meier A, Bagchi A, Sidhu HK, Alter G, Suscovich TJ, Kavanagh DG, et al. Upregulation of PD-L1 on monocytes and dendritic cells by HIV-1 derived TLR ligands. AIDS. 2008; 22: 655-658.

149. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006; 443: 350-354.

150. Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol. 2003; 170: 1257-1266.

151. Freeman GJ, Wherry EJ, Ahmed R, Sharpe AH. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med. 2006; 203: 2223-2227.

152. Brandt L, Benfield T, Mens H, Clausen LN, Katzenstein TL, Fomsgaard A, et al. Low level of regulatory T cells and maintenance of balance between regulatory T cells and TH17 cells in HIV-1-infected elite controllers. J Acquir Immune Defic Syndr. 2011; 57: 101-108.

153. Kanwar B, Favre D, McCune JM. Th17 and regulatory T cells: implications for AIDS pathogenesis. Curr Opin HIV AIDS. 2010; 5: 151-157.

154. Miura Y, Misawa N, Maeda N, Inagaki Y, Tanaka Y, Ito M, et al. Critical contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to apoptosis of human CD4+ T cells in HIV-1-infected hu-PBL-NOD-SCID mice. J Exp Med. 2001; 193: 651-660.

155. Lichtner M, Marañón C, Vidalain PO, Azocar O, Hanau D, Lebon P, et al. HIV type 1-infected dendritic cells induce apoptotic death in infected and uninfected primary CD4 T lymphocytes. AIDS Res Hum Retroviruses. 2004; 20: 175-182.

156. Weiss L, Donkova-Petrini V, Caccavelli L, Balbo M, Carbonneil C, Levy Y. Human immunodeficiency virus-driven expansion of CD4+CD25+ regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. Blood. 2004; 104: 3249-3256.

157. Chase AJ, Yang HC, Zhang H, Blankson JN, Siliciano RF. Preservation of FoxP3+ regulatory T cells in the peripheral blood of human immunodeficiency virus type 1-infected elite suppressors correlates with low CD4+ T-cell activation. J Virol. 2008; 82: 8307-8315.

158. Sereti I, Imamichi H, Natarajan V, Imamichi T, Ramchandani MS, Badralmaa Y, et al. In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients. J Clin Invest. 2005; 115: 1839-1847.

159. Nilsson J Boasso A, Velilla PA, Zhang R, Vaccari M, Franchini G, et al. HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. Blood. 2006; 108: 3808-3817.

1060. Epple HJ, Loddenkemper C, Kunkel D, Tröger H, Maul J, Moos V, et al. Mucosal but not peripheral FOXP3+ regulatory T cells are highly increased in untreated HIV infection and normalize after suppressive HAART. Blood. 2006; 108: 3072-3078.

161. Andersson J, Boasso A, Nilsson J, Zhang R, Shire NJ, Lindback S, et al. The prevalence of regulatory T cells in lymphoid tissue is correlated with viral load in HIV-infected patients. J Immunol. 2005; 174: 3143- 3147.

162. Kinter AL, Hennessey M, Bell A, Kern S, Lin Y, Daucher M, et al. CD25(+)CD4(+) regulatory T cells from the peripheral blood of asymptomatic HIV-infected individuals regulate CD4(+) and CD8(+) HIV-specific T cell immune responses in vitro and are associated with favorable clinical markers of disease status. J Exp Med. 2004; 200: 331-343.

163. Kinter AL, Horak R, Sion M, Riggin L, McNally J, Lin Y, et al. CD25+ regulatory T cells isolated from HIV-infected individuals suppress the cytolytic and nonlytic antiviral activity of HIV-specific CD8+ T cells in vitro. AIDS Res Hum Retroviruses. 2007; 23: 438-450.

164. Sharma MD, Baban B, Chandler P, Hou DY, Singh N, Yagita H, et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest. 2007; 117: 2570-2582.

165. Kaufmann DE, Kavanagh DG, Pereyra F, Zaunders JJ, Mackey EW, Miura T, et al. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol. 2007; 8: 1246-1254.

166. Leng Q, Bentwich Z, Magen E, Kalinkovich A, Borkow G. CTLA-4 upregulation during HIV infection: association with anergy and possible target for therapeutic intervention. AIDS. 2002; 16: 519- 529.

167. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003; 198: 1875-1886.

168. Martinez-Navio JM, Casanova V, Pacheco R, Naval-Macabuhay I, Climent N, Garcia F, et al. Adenosine deaminase potentiates the generation of effector, memory, and regulatory CD4+ T cells. J Leukoc Biol. 2011; 89: 127-136.

169. Casanova V, Naval-Macabuhay I, Massanella M, Rodríguez-García M, Blanco J, Gatell JM, et al. Adenosine deaminase enhances the immunogenicity of human dendritic cells from healthy and HIVinfected individuals. PLoS One. 2012; 7: e51287.

170. Gakis C, Calia G, Naitana A, Pirino D, Serru G. Serum adenosine deaminase activity in HIV positive subjects. A hypothesis on the significance of ADA2. Panminerva Med. 1989; 31: 107-113.

Received : 22 Feb 2014
Accepted : 03 Mar 2014
Published : 04 Mar 2014
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
TEST Journal of Dentistry
ISSN : 1234-5678
Launched : 2014
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X